Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H12Cl2O4 |
Molecular Weight | 303.138 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl
InChI
InChIKey=AVOLMBLBETYQHX-UHFFFAOYSA-N
InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
Molecular Formula | C13H12Cl2O4 |
Molecular Weight | 303.138 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB00903Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/16092s042,16093s044lbl.pdf
Sources: http://www.drugbank.ca/drugs/DB00903
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/16092s042,16093s044lbl.pdf
Ethacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis. Ethacrynic acid inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. Diuretics also lower blood pressure initially by reducing plasma and extracellular fluid volume; cardiac output also decreases, explaining its antihypertensive action. Eventually, cardiac output returns to normal with an accompanying decrease in peripheral resistance. Its mode of action does not involve carbonic anhydrase inhibition. Ethacrynic acid is indicated for the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Glutathione transferases, rat liver Sources: https://www.ncbi.nlm.nih.gov/pubmed/27457758 |
|||
Target ID: GO:0006927 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26950276 |
|||
Target ID: P05023|||Q9UJ20 Gene ID: 476.0 Gene Symbol: ATP1A1 Target Organism: Homo sapiens (Human) Sources: http://www.drugbank.ca/drugs/DB00903 |
|||
Target ID: CHEMBL1874 Sources: http://www.drugbank.ca/drugs/DB00903 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | EDECRIN Approved UseEDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those
commonly employed is required.
1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease,
including the nephrotic syndrome.
2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.
3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease
or the nephrotic syndrome.
4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute
pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. Launch Date1967 |
|||
Primary | EDECRIN Approved UseEDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those
commonly employed is required.
1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease,
including the nephrotic syndrome.
2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema.
3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease
or the nephrotic syndrome.
4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute
pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. Launch Date1967 |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg 2 times / day multiple, oral Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sex: unknown Sources: |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (severe) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | severe Disc. AE |
50 mg 2 times / day multiple, oral Dose: 50 mg, 2 times / day Route: oral Route: multiple Dose: 50 mg, 2 times / day Sources: |
unhealthy Health Status: unhealthy Sex: unknown Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Cyclo-oxygenase and lipoxygenase pathways in mast cell dependent-neurogenic inflammation induced by electrical stimulation of the rat saphenous nerve. | 2001 Apr |
|
3-Methyleneoxindole: an affinity label of glutathione S-transferase pi which targets tryptophan 38. | 2001 Jun 26 |
|
Ethacrynic acid inhibits pancreatic exocrine secretion. | 2001 Nov |
|
Solutol and cremophor products as new additives in suppository formulation. | 2002 |
|
Analysis of myogenic mechanisms in renal autoregulation. | 2002 Apr |
|
Toxicity of ethacrynic acid in isolated rat hepatocytes. | 2002 Apr |
|
Influence of antioxidant depletion on nitrergic relaxation in the pig gastric fundus. | 2002 Feb |
|
Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers. | 2002 Feb |
|
Inhibition of glutathione S-transferases by antimalarial drugs possible implications for circumventing anticancer drug resistance. | 2002 Feb 10 |
|
Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. | 2002 Jan 16 |
|
Characteristics of the plasma membrane Cl(-)-ATPase of the bream (Abramis brama) brain sensitive to the inhibitory receptor ligands. | 2002 Jan-Feb |
|
Purification and characterization of a novel glutathione S-transferase from Asaphis dichotoma. | 2002 Jul 15 |
|
Antimicrobial peptides initiate IL-1 beta posttranslational processing: a novel role beyond innate immunity. | 2002 Mar 15 |
|
Modulation of pumpkin glutathione S-transferases by aldehydes and related compounds. | 2003 May |
|
Improved neural representation of vowels in electric stimulation using desynchronizing pulse trains. | 2003 Oct |
|
Characterization and molecular cloning of a glutathione S-transferase from the whitefly Bemisia tabaci (Hemiptera: Aleyrodidae). | 2004 Apr |
|
The influence of anti-irritants on captopril hydrophilic gel. | 2004 Feb |
|
Transport of 99mTc-MAG3 via rat renal organic anion transporter 1. | 2004 Jan |
|
Time course of efferent fiber and spiral ganglion cell degeneration following complete hair cell loss in the chinchilla. | 2004 Jan 30 |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Can also be used iv:
The usual intravenous dose for the average sized adult is 50 mg, or 0.5 to 1.0 mg per kg of body weight. Usually only one dose has been necessary; occasionally a second dose at a new injection site, to avoid possible
thrombophlebitis, may be required. A single intravenous dose not exceeding 100 mg has been used in critical situations
Dosage: To Initiate Diuresis
In Adults: The smallest dose required to produce gradual weight loss (about 1 to 2 pounds per day) is
recommended. Onset of diuresis usually occurs at 50 to 100 mg for adults. After diuresis has been achieved, the minimally effective dose (usually from 50 to 200 mg daily) may be given on a continuous or intermittent dosage schedule.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26950276
Ethacrynic acid (10uM) induced both apoptosis and necroptosis in primary CLL cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 09:43:25 GMT 2025
by
admin
on
Wed Apr 02 09:43:25 GMT 2025
|
Record UNII |
M5DP350VZV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C49184
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
||
|
WHO-VATC |
QC03CC01
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
||
|
WHO-ATC |
C03CC01
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
||
|
LIVERTOX |
380
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
||
|
NDF-RT |
N0000175590
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
||
|
NDF-RT |
N0000175366
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2136
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
1651
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
4876
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
1071
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
DB00903
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
C485
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
62349
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
ALTERNATIVE | |||
|
M5DP350VZV
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
85791
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
1256004
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
200-384-1
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
100000082366
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
7179
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
D004976
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
ETACRYNIC ACID
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
58-54-8
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
CHEMBL456
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
624008
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
SUB07255MIG
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
3278
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
4109
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
M5DP350VZV
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
m5042
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID3025257
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY | |||
|
Ethacrynic Acid
Created by
admin on Wed Apr 02 09:43:25 GMT 2025 , Edited by admin on Wed Apr 02 09:43:25 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
DEGRADENT -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
DEGRADENT -> PARENT |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
POTENCY
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|